Moawia Mohammed Ali Elhassan, Associate Professor at the University of Gezira, shared a post on LinkedIn about a paper by Maia Dzhugashvili et al. published in International Journal of Radiation Oncology, Biology, Physics:

“A recently published case series in the Journal of Radiation Oncology – Biology – Physics demonstrated the clinical feasibility and safety of adjuvant ultrahypofractionated radiotherapy with simultaneous integrated boost (SIB) of 29 Gy to the tumor bed in patients with early-stage breast cancer, showing no excess of early adverse events. The authors recommend further investigation into late toxicities.”

“Ultrahypofractionation and Simultaneous Integrated Boost in Breast Cancer: Early Side Effects Analysis”

Authors: Maia Dzhugashvili, Ana Serradilla, Jaume Fernández-Ibiza, Graciela García, Kirill Matskov Malinochka, Lisellot Torres, Antonio Serala, José Begara, Daniela Gonsalves, Juan José De la Cruz Troca, Philip Poortmans, Felipe Couñago, Escarlata López.

$Moawia Mohammed Ali Elhassan: Ultrahypofractionated radiotherapy with SIB shows early safety in breast cancer$

More posts featuring Moawia Mohammed Ali Elhassan.